APA (7th ed.) Citation

YC, L., BL, C., CY, H., LY, C., SJ, L., GYH, L., . . . CY, H. (2025). Propafenone- vs. amiodarone-associated adverse cardiac outcomes in patients with atrial fibrillation and heart failure. British journal of clinical pharmacology, 91(9), 2567. https://doi.org/10.1002/bcp.70068

Chicago Style (17th ed.) Citation

YC, Lin, Chen BL, Hsu CY, Chen LY, Lin SJ, Lip GYH, Chien LN, and Huang CY. "Propafenone- Vs. Amiodarone-associated Adverse Cardiac Outcomes in Patients with Atrial Fibrillation and Heart Failure." British Journal of Clinical Pharmacology 91, no. 9 (2025): 2567. https://doi.org/10.1002/bcp.70068.

MLA (9th ed.) Citation

YC, Lin, et al. "Propafenone- Vs. Amiodarone-associated Adverse Cardiac Outcomes in Patients with Atrial Fibrillation and Heart Failure." British Journal of Clinical Pharmacology, vol. 91, no. 9, 2025, p. 2567, https://doi.org/10.1002/bcp.70068.